Vaccine News and Research

Latest Vaccine News and Research

Measles vaccine does not increase risk of autism in children, reveals Polish study

As a pivotal paper linking childhood vaccinations to autism is discredited, a new study finds no evidence that the measles vaccine—given alone or as part of a combined measles, mumps, and rubella (MMR) vaccine—increases the risk of autism in children. The study appears in The Pediatric Infectious Disease Journal (www.pidj.com), published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

10 Feb 2010

TBTC to receive more than $90 million to develop effective tuberculosis treatments

The Tuberculosis Trials Consortium (TBTC) strives to conduct research about the diagnosis, medical treatment, and prevention of tuberculosis (TB) infection and disease. The network is composed of a partnership of clinical investigators from the U.S. Centers for Disease Control and Prevention (CDC), public health departments from different countries, as well as medical and pharmaceutical institutions.

10 Feb 2010

Dana-Farber Cancer Institute, Sanford-Burnham Medical Research Institute sign license agreement with Genentech, Roche

10 Feb 2010

NIAID awards Tulane University over $15M to develop Lassa fever vaccine and treatment

The National Institute of Allergies and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded a five-year contract totaling $15,254,919 to Tulane University for its ongoing efforts to treat and prevent Lassa fever, an often deadly viral disease that threatens hundreds of thousands of people annually in West Africa and is classified as a potential bioterrorism threat.

10 Feb 2010

Health officials encourage caution, despite H1N1 case decline

As the number of new H1N1 (swine flu) infections worldwide drops, U.S. health officials on Friday cautioned the virus continues to circulate and can still be deadly, Reuters reports. According to the WHO, H1N1 remains the dominant strain worldwide, but there are reports of the recent emergence of the seasonal flu in Africa and China, according to the news agency.

10 Feb 2010

Advaxi to receive fund from CRUK for clinical trial of ADXS11-001

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, is pleased to announce that Cancer Research UK (CRUK), the UK philanthropy dedicated to cancer research, has agreed to fund the cost of a clinical trial to investigate the use of ADXS11-001, Advaxis’ lead human papilloma virus (HPV)-directed vaccine candidate, for the treatment of head and neck cancer.

10 Feb 2010

Whooping cough vaccine may be losing its punch: study

Vaccination programs against whooping cough may not be fully effective because the bacteria that cause the disease have evolved new strains, a new study has found.

9 Feb 2010

USPTO awards NexBio patent covering sialidase pharmaceutical compositions and methods of treating influenza

NexBio, Inc. today announced the issuance by the United States Patent and Trademark Office of United States Patent No. 7,645,448 entitled "Class of Therapeutic Protein Based Molecules". This patent covers NexBio's sialidase pharmaceutical compositions, including its lead compound DAS181 (Fludase®), and methods of treating or preventing viral infection by influenza and parainfluenza with such compositions.

9 Feb 2010

NIH awards over $15M for Tulane University's collaborative effort to combat VHF

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, and Tulane University, today announced a major extension of the collaborative effort to combat viral hemorrhagic fever (VHF), an effort that will generate an additional $800,000 in contract revenue for Corgenix over the life of the contract.

9 Feb 2010

Novavax announces new data from trivalent seasonal influenza VLP vaccine study

Novavax, Inc. announced today new data from a clinical study that began in May of 2009 among healthy adults 18 to 49 years of age with Novavax's trivalent seasonal influenza Virus-like Particle (VLP) vaccine. The vaccine matched the influenza strains recommended for the 2008-2009 influenza season including H1N1 A/Brisbane/59/2007, H3N2 A/Brisbane/10/2007, and B/Florida/04/2006 strains.

9 Feb 2010

Dana-Farber Cancer Institute and Sanford-Burnham Medical Research Institute sign license agreement with Genentech

Dana-Farber Cancer Institute and the Sanford-Burnham Medical Research Institute have signed a license agreement with Genentech, a wholly owned member of the Roche group, and Roche, that grants the companies exclusive rights to manufacture, develop and market human monoclonal antibodies to treat and protect against group 1 influenza viruses. These viruses include the strains for the current seasonal and H1N1 influenzas. Genentech and Roche also have a non-exclusive right to manufacture, develop and market diagnostic tests for group 1 influenza.

9 Feb 2010

GeoVax Labs provides updates on HIV-1 vaccine trials

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today provided an update on its vaccine trials progress.

9 Feb 2010

Inovio Biomedical announces additional immunogenicity data from therapeutic cervical cancer vaccine trial

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today additional interim safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18 and is delivered via in vivo electroporation.

8 Feb 2010

Market Media Connect retained as Northwest Biotherapeutics' communications agency of record

Northwest Biotherapeutics, Inc., a development stage biotechnology company focused on personalized cancer vaccines to enhance immune system responses to tumors, has retained Market Media Connect as their communications agency of record. Led from its Los Angeles headquarters, Market Media Connect will support Northwest's communication objectives as the company moves into the next phase of its development.

8 Feb 2010

Novavax to discontinue collaboration agreement with ROVI Pharmaceuticals

Novavax, Inc. announced today that the company has decided to discontinue negotiations in its pursuit of the previously announced collaboration with ROVI Pharmaceuticals to develop Novavax's virus-like-particle (VLP)-based vaccines against influenza in the country of Spain.

8 Feb 2010

Smokers more likely to vaccinate their daughters against HPV

A parent's existing health habits or behaviors, like cigarette smoking, may influence the likelihood that they will have their daughters vaccinated against HPV.

8 Feb 2010

HTDS announces recent business developments

Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) brings attention to a certain previously released news announcements namely January 7 2009, November 19, 2009, Dec 15, 2009 January 12,2010, and January 22, 2010.

6 Feb 2010

HPV vaccination programs may reduce genital diseases

High-coverage human papillomavirus (HPV) vaccinations among adolescents and young women may result in a rapid reduction of genital warts, cervical cell abnormalities, and diagnostic and therapeutic procedures, researchers report in a new study published online February 5 in the Journal of the National Cancer Institute. Some of these genital abnormalities are precursors of cervical, vulvar, and vaginal cancers.

6 Feb 2010

Breakthrough research could lead to new potential treatments for malaria

Groundbreaking research done at Singapore's Nanyang Technological University's (NTU) School of Biological Sciences (SBS) could lead to the development of more potent drugs or a vaccine for malaria, which is transmitted to humans by infected mosquitoes and kills up to three million people each year.

6 Feb 2010

Majority of Americans believe flu outbreak is over; levels of concern continue to decline

The latest poll from researchers at the Harvard School of Public Health (HSPH) shows that almost half of Americans believe the H1N1 flu outbreak is over (44%), and levels of concern about getting sick with the virus continue to decline.

6 Feb 2010

Vaccine News and Research

Latest Vaccine News and Research

Measles vaccine does not increase risk of autism in children, reveals Polish study

TBTC to receive more than $90 million to develop effective tuberculosis treatments

Dana-Farber Cancer Institute, Sanford-Burnham Medical Research Institute sign license agreement with Genentech, Roche

NIAID awards Tulane University over $15M to develop Lassa fever vaccine and treatment

Health officials encourage caution, despite H1N1 case decline

Advaxi to receive fund from CRUK for clinical trial of ADXS11-001

Whooping cough vaccine may be losing its punch: study

USPTO awards NexBio patent covering sialidase pharmaceutical compositions and methods of treating influenza

NIH awards over $15M for Tulane University's collaborative effort to combat VHF

Novavax announces new data from trivalent seasonal influenza VLP vaccine study

Dana-Farber Cancer Institute and Sanford-Burnham Medical Research Institute sign license agreement with Genentech

GeoVax Labs provides updates on HIV-1 vaccine trials

Inovio Biomedical announces additional immunogenicity data from therapeutic cervical cancer vaccine trial

Market Media Connect retained as Northwest Biotherapeutics' communications agency of record

Novavax to discontinue collaboration agreement with ROVI Pharmaceuticals

Smokers more likely to vaccinate their daughters against HPV

HTDS announces recent business developments

HPV vaccination programs may reduce genital diseases

Breakthrough research could lead to new potential treatments for malaria

Majority of Americans believe flu outbreak is over; levels of concern continue to decline

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in